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Abstract
MUC1 is an oncoprotein that is overexpressed in up to 90% of breast carcinomas. A previous in vitro study by our group
demonstrated that the cytoplasmic domain of MUC1 (MUC1-CD), the minimal functional unit of MUC1, contributes to the
malignant phenotype in cells by binding directly to b-catenin and protecting b-catenin from GSK3b-induced degradation.
To understand the in vivo role of MUC1-CD in breast development, we generated a MUC1-CD transgenic mouse model
under the control of the MMTV promoter in a C57BL/6J background, which is more resistant to breast tumor. We show that
the expression of MUC1-CD in luminal epithelial cells of the mammary gland induced a hyperplasia phenotype
characterized by the development of hyper-branching and extensive lobuloalveoli in transgenic mice. In addition to this
hyperplasia, there was a marked increase in cellular proliferation in the mouse mammary gland. We further show that
MUC1-CD induces nuclear localization of b-catenin, which is associated with a significant increase of b-catenin activity, as
shown by the elevated expression of cyclin D1 and c-Myc in MMTV-MUC1-CD mice. Consistent with this finding, we
observed that overexpression of MUC1-C is associated with b-catenin nuclear localization in tumor tissues and increased
expression of Cyclin D1 and c-Myc in breast carcinoma specimens. Collectively, our data indicate a critical role for MUC1-CD
in the development of mammary gland preneoplasia and tumorigenesis, suggesting MUC1-CD as a potential target for the
diagnosis and chemoprevention of human breast cancer.
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Introduction
The mammary gland is composed of a ductal epithelium and
surrounding stroma. Development of the mammary gland is initiated
with the formation of a small ductal tree in the embryo but progresses
predominantly after birth in defined stages associated with sexual
development and reproduction, including prepuberty, puberty,
pregnancy, lactation, and involution. The primary mammary tissue
remains quiescent until puberty, and upon stimulation of circulating
growth hormone and estrogen, the distal end of the duct enlarges to
form a bulb-like terminal end bud (TEB), which is a highly
proliferative epithelial structure. TEBs drive the epithelial ductal tree
to elongate and branch rapidly, leading to the formation of an
extended ductal system that fills the entire fat pad. The ducts branch
into smaller ductules and develop alveoli during pregnancy, which
then differentiate into secretory epithelial cells during parturition.
The ductal system is surrounded by a continuous periductal stroma
that consists of fibroblasts, macrophages, eosinophils and vascular
cells within the confines of the mammary fat pad [1,2].
Many genetic pathways have been identified as being involved
in mammary development [1]. Among these pathways, Wnt/b-
catenin signaling has been documented to have critical functions
during mammary bud patterning, its formation during embryo-
genesis and its elongation during puberty, as well as in the
development of milk production during pregnancy [3,4,5]. The
canonical Wnt or Wnt/b-catenin pathway operates by inhibiting
proteolysis of cytoplasmic b-catenin, allowing it to enter the
nucleus and regulate gene transcription through the lymphoid
enhancer factor/T cell factor (Lef/Tcf) transcription factors,
thereby promoting cell proliferation and survival [6]. Both loss-of-
function and gain-of-function studies suggest that Wnt signaling is
of importance during alveolar development [3,7]. It may promote
ductal side-branching in early pregnancy and may be essential for
the proliferation and survival of lobuloalveolar progenitor cells in
later pregnancy. In addition to regulating mammary development,
the Wnt/b-catenin pathway is also associated with breast cancer.
Expression of MMTV-DN89b-catenin induces precocious lobu-
loalveolar development and multiple aggressive adenocarcinomas
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19102early in life [8]. Moreover, activation of b-catenin signaling in
basal mammary epithelial cells was also found to affect the entire
process of mammary gland development and give rise to tumors
[9].
The transmembrane protein mucin MUC1 is expressed on most
apical surfaces of secretory epithelia, including the mammary
gland, as well as some hematopoietic cells. It was initially identified
as a human breast tumor antigen because it was aberrantly
overexpressed in more than 70% of human carcinomas with a loss
of polarity, special in 90% of human breast carcinomas [10,11].
Overexpression of MUC1 has been shown to confer anchorage-
independent growth and tumorigenicity in cells [12,13]. Studies
using mouse models have further established roles for MUC1 in
the promotion and invasiveness of breast cancer. Overexpression
of human MUC1 in MMTV-MUC1 transgenic mice indicated
the ability of MUC1 to promote in vivo transformation of the
mammary gland by forming a complex with b-catenin and
potentiating EGF-dependent activation of MAP kinase signaling
pathways, thereby inhibiting normal glandular involution[14,15].
A recent study also showed the ability of Muc1 to control the
development and tumorigenesis of myeloid-derived suppressor
cells (MDSCs) [16]. However, a deficiency of Muc1 results in both
reduced tumor growth and spreading in MMTV1-mTag mice
[17].
The human MUC1 gene spans 4 to 7 kb [18]. Following
translation as a large precursor polypeptide, it is cleaved into N-
and C-terminal subunits in the endoplasmic reticulum, and the
two subunits form a stable noncovalent complex at the cell
membrane. The MUC1 NH2-terminal subunit (MUC1-N)
consists of variable numbers of highly glycosylated 20-amino-acid
tandem repeats (.250 kDa) [19] that contribute to a physical
barrier protecting epithelial cells from damage due to external
environmental exposure. The MUC1 COOH-terminal subunit
(MUC1-C) is composed of a 58-amino-acid extracellular domain,
a 28-amino-acid transmembrane domain, and a 72-amino-acid
cytoplasmic domain. Glycosylation on Asn36 of the MUC1-C
extracellular domain induces MUC1 to bind to the galectin-3
ligand and physically associate with the epidermal growth factor
receptor (EGFR) [15,20] and other receptor tyrosine kinases. The
MUC1-C cytoplasmic domain (MUC1-CD) contains seven Tyr
residues, five of which can act as binding motifs for proteins with
SH2 domains when phosphorylated. Moreover, the MUC1-CD
contains a serine-rich motif (SRM) with homology to sequences in
E-cadherin and APC protein that function as b-catenin binding
sites [21]. GSK3b phosphorylates MUC1-CD on a serine in an
SPY site that is just upstream of the SRM [22]. The
phosphorylation of MUC1-CD by GSK3b decreases the interac-
tion with b-catenin [22]. Conversely, both src and erbB receptor
tyrosine kinases phosphorylate MUC1, as well as the serine/
threonine kinase protein kinase C delta (PKCd), and these
phosphorylation events promote interactions between b-catenin
and MUC1 [15,23,24]. Importantly, MUC1-C is detectable in the
nucleus [25,26] and functions as a coactivator of b-catenin-Tcf–
mediated transcription in cells [27].
Our previous studies showed that MUC1-CD binds directly to
b-catenin and blocks the GSK3b-mediated phosphorylation and
degradation of b-catenin, thereby contributing to the malignant
phenotype in cells [12]. However, the role of MUC1-CD in
mammary development has only been partially elucidated. In the
current study, we generated a mouse mammary tumor virus
(MMTV)-MUC1-CD transgenic mouse model and investigated
the function of MUC1-CD in mammary development in a
C57BL/6J background mouse that is more resistant to breast
tumorigenesis.
Results
MUC1-CD is expressed in luminal epithelial cells of the
mammary gland
To investigate the role of MUC1-CD in mammary develop-
ment, we generated transgenic mice that overexpress GFP-tagged
human MUC1-CD (72 AA) cDNA under the control of an
MMTV promoter [28,29] in the mammary gland with the
construct shown in Fig. 1A. Four founders with genomic
integration of the transgene were obtained by PCR analysis of
tail gDNA from potential MMTV-GFP-MUC1-CD (MUC1-CD)
founder transgenic mice (data not show). Three of these
individuals (L43,L49 and L80) displayed Mendelian transmission
to the F1 generation and expressed the transgene, as determined
by RT-PCR using total RNA (Fig. 1B). The band is not found in
wild-type littermates or negative controls that did not contain the
template (Fig. 1B). To test the tissue specificity of transgene
expression, RT-PCR was further performed using total RNA from
the mammary gland, salivary gland, lung, ovary and kidney from a
L43 virgin 8w female transgenic mouse [30]. The results showed
that MUC1-CD was detectable in the mammary gland and weakly
expressed in the salivary gland. Little, if any, expression was
detected in the lung, ovary and kidney (Fig. 1C). To determine the
distribution of MUC1-CD, immunofluorescence staining for anti-
GFP in the frozen sections was carried out in the mammary glands
at pregnancy day 13.5 of MUC1-CD transgenic mice and wild-
type littermates. The results indicated that the GFP-MUC1-CD
was expressed in the cytoplasm and nuclei of epithelial cells in
transgenic mouse mammary ducts, and no expression was
detectable in wild-type littermates (Fig. 1D).
MUC1-CD induces mammary hyperplasia in transgenic
mice
To determine whether MUC1-CD has effects on mammary
development, the inguinal mammary glands from four mice of 8-
wk-old virgin females for each group were excised and compared
between MMTV-GFP-MUC1-CD transgenic mice and wild-type
littermates. The mammary glands of the transgenic mice appeared
larger in volume than that of wild-type littermates (Fig. 2A). A
statistically significant difference (p,0.05) was found when we
compared the weight/body ratio of the inguinal mammary gland
between transgenic mice and wild-type littermates in 8-wk-old
virgins and pregnant females (Fig. 2B). To investigate this in more
detail, we examined whole-mount preparations of the inguinal
mammary glands from early virgin females of MUC1-CD
transgenic mice and wild-type littermates. In 2-wk-old virgins,
precocious development of mammary epithelial ducts was
observed in transgenic mice compared with wildtype littermates
(Fig. 2C upper). Marked differences were seen in 5-wk-old virgin
transgenic and wild-type mice. Wild-type mammary ducts
extended to the lymph node, while transgenic mammary ducts
extended beyond the lymph node and exhibited an extent of
elongation (Fig. 2C lower). In addition, transgenic mammary
tissue displayed a nearly 100% increase in terminal end buds
(TEBs) and a 80% increase in end bud (EB) structures compared
to wild-type littermates (Fig. 2D).
The mammary glands from 8-wk-old virgins were further
examined at higher magnifications. The mammary ductal tree
from the transgenic mice displayed a more complex structure than
that from wild-type mice (Fig. 3A upper panel). In addition,
branch-point analysis indicated a statistically significant increase in
branching in transgenic mice (Fig. 3B). Transgenic mammary
glands also showed precocious development of lobuloalveoli in
females at 8.5 days of pregnancy compared with stage-matched
MUC1-CD Induces Mammary Hyperplasia
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e19102Figure 1. Generation of MMTV-MUC1-CD transgenic mice. (A) Schematic representation of the transgene construct. MMTV-LTR, mouse
mammary tumor virus long terminal repeat; b, b-globin intron/exon/poly A sequences; B, BamHI; X, XhoI. (B) RT-PCR analysis of GFP-MUC1-CD and b-
actin expression in day 13.5 pregnant mouse mammary glands. WT, Wild-type; L43, L49, and L80 indicate cDNA from Lines 43, 49 and 80, respectively;
NCTL, negative control, PCR without template. (C) RT-PCR analysis of GFP-MUC1-CD and b-actin expression in the indicated organs of an L43 adult
female mouse. (D) IF staining of GFP performed on frozen sections of wild-type (upper panel) and transgenic mouse mammary glands (lower panel)
at day 13.5 of pregnancy. Nuclei were stained with DAPI. The slides were analyzed by flourescence microscopy. Similar results were obtained with the
separately mice. Photomicrographs obtained at a 4006magnification.
doi:10.1371/journal.pone.0019102.g001
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MUC1-CD is sufficient for promoting ductal branching and the
formation of alveolar lobules. To further investigate the structure
of mammary ducts, hematoxylin and eosin (H&E) staining was
performed on paraffin sections from females at 8.5 days of
pregnancy, and a large number of cells were found in the
mammary gland lumen of transgenic mice but not in wild-type
littermates, indicating a luminal epithelium hyperplasia phenotype
in the transgenic mice (Fig. 3C). To determine whether MUC1-
CD also effect on mammary gland of male mice, which without
ovarian hormonal function, we analyzed 3 pairs of whole-mount
preparations of the inguinal mammary glands from 6-month-old
male and 20-month-old male mice. We found that transgenic mice
showed a hyperbranch phenotype when compared with their wild-
type littermates (Fig. 3D). These data demonstrate that expression
of MUC1-CD induces mammary gland hyper-branching in both
of female and male mice and extensive lobulo-alveolar develop-
ment in female, these are associated with a hyperplasia phenotype.
MUC1-CD promotes mammary cellular proliferation
In light of the finding that MUC1-CD induces the development
ofmammaryhyper-branchingand extensivelobuloalveoli,weasked
whether MUC1-CD expression was associated with enhanced
cellular proliferation or reduced apoptosis. Measurement of
mammary cell proliferation was performed based on BrdU
incorporation in 8-wk-old virgins and females at day 8.5 and 13.5
of pregnancy. The results revealed that there were more BrdU-
positiveepithelialcellsinthemammaryglandluminaofMUC1-CD
transgenic mice than that in wild-type mice at all three stages
(Fig. 4A). Quantitative analysis indicated that statistically significant
differences were found for the number of BrdU-positive cells
between MUC1-CD transgenic mice and wild-type littermates at all
three stages (virgin 8 week: 3.361.1% versus 1.460.4%, P=0.045;
8.5 days pregnant: 7.760.3% versus 5.560.6%, P=0.006; 13.5
days pregnant: 9.860.4% versus 7.460.6%, P=0.005) (Fig. 4B).
However, TUNEL staining assays at these three stages showed no
detectable difference between transgenic mice and wild-type
littermates (data not shown). These data demonstrate that
overexpression of MUC1-CD promotes cellular proliferation in
the mammary glands of transgenic mice.
MUC1-CD increases b-catenin nuclear localization and
activity in the mouse mammary gland
Previous studies have demonstrated that MUC1-CD overex-
pression promotes cell proliferation in vitro via stabilization of b-
catenin [12]. To dissect the mechanism underlying the effect of
MUC1-CD on mammary cellular proliferation in vivo, we
investigated the expression of b-catenin in 8-wk-old virgin and
Figure 2. MUC1-CD induces precocious development of mammary glands during prepuberty and early puberty. (A) Mammary glands
from a MUC1-CD transgenic female mouse (right) and a wild-type littermate (left). (B) Comparison of the weight/body ratio of the fourth mammary
glands between MUC1-CD transgenic mice (n=4) and wild-type littermates (n=4). (C) Carmine alum staining of whole mounts of inguinal mammary
glands from a wild-type female (left) and transgenic female (right) in 2-wk-old virgins (upper) and 5-wk-old virgins (lower). As indicated by the arrows,
in 2-wk-old virgins, the precocious development of mammary epithelial ducts was apparently observed in transgenic mice (upper right) compared to
wild-type littermates (upper left). (D) Quantification of the number of terminal end buds (TEBs) and end buds (EBs) in MUC1-CD transgenic mice
(n=3) and wild-type littermates (n=3) at 5 wks of age. *P,0.05; **P,0.01.
doi:10.1371/journal.pone.0019102.g002
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demonstrated a clear expression of b-catenin in both MUC1-CD
transgenic mice and wild-type mice, but the abundance of b-
catenin protein was found to be much higher in MUC1-CD
transgenic mice than in wild-type littermates (Fig. 5A). In addition,
b-catenin was located predominantly in the nucleus at both of
these stages in MUC1-CD transgenic mice (Fig. 5A right panel). In
contrast, in wild-type mice, it was located mainly in the cytosol and
cell membrane. In support of this finding, subcellular fractionation
experiments in females at day 13.5 of pregnancy showed that the
b-catenin level was increased in the nucleus in MUC1-CD
transgenic mice compared to wild-type mice (Fig. 5B). A similar
result was obtained for 8-wk-old virgin mice (Data not shown).
Cyclin D1 and c-Myc are two important transcriptional targets of
the Wnt/b-catenin pathway [31,32,33]. To further elucidate the
activity of b-catenin, we examined the expression of these two
genes in mammary tissues in 8-wk-old virgins and females at day
8.5 and 13.5 of pregnancy. Consistent with the increased activity
of b-catenin, MUC1-CD transgenic mice displayed markedly
increased mRNA levels of c-Myc, as well as elevated levels of
cyclin D1 (Fig. 5C and D). These results were further confirmed by
the elevated protein levels of c-Myc and cyclin D1 in MUC1-CD
transgenic mice (Fig. 5E). Taken together, these data indicate that
MUC1-CD induces the nuclear distribution of b-catenin and
Figure 3. MUC1-CD induces a lobular hyperplasia phenotype in the mammary gland. (A) Whole mounts of inguinal mammary glands from
wild-type (left) and transgenic (right) mice at 8 wks (upper panel) and pregnancy day 8.5 (lower). Insets in each panel are higher magnifications
(200X), scale bars, 0.6 mm, LN: lymph node. (B) Branch-point analysis in MUC1-CD transgenic mice (n=3) and wild-type littermates (n=3) at 8 wks of
age. P,0.01. (C) H&E staining of sections from mammary glands of wild-type (left) and transgenic (right) mice at pregnancy day 8.5. As indicated by
the arrow, cells filled the ducts of transgenic mammary glands. All images were acquired at the same magnification; scale bars, 30 mm. (D)
Representative images of inguinal mammary glands whole mounts from wild-type (upper) and transgenic (lower) male mice at 6 months. Insets in
each panel are higher magnifications.
doi:10.1371/journal.pone.0019102.g003
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in the mouse mammary gland.
MUC1-C is associated with increased b-catenin nuclear
localization and activity in clinical breast carcinomas
To explore the relationship between MUC1-C expression and
b-catenin activity in human breast cancers, we conducted IHC
analysis of MUC1-C, b-catenin, c-Myc and Cyclin D1 in human
breast cancers and normal tissues. In the normal mammary gland
tissues, MUC1-C was expressed weakly on the apical surface of
glandular epithelia (Fig. 6A upper left), while b-catenin was mainly
localized to the adherens junctions of mammary epithelium cells
(Fig. 6A lower left). In contrast, in the human breast cancer
specimens, MUC1-C was aberrantly overexpressed in the cytosol
and nuclei (Fig. 6A upper right). Additionally, significantly more b-
catenin was localized to the nucleus in breast cancer specimens
(Fig. 6A lower right). Consistent with this result, Cyclin D1 and c-
Myc were expressed at considerably higher levels in tumors
Figure 4. MUC1-CD promotes cellular proliferation of the mammary gland. (A) Representative images of BrdU assays. BrdU was
administered intraperitoneally to mice at 8 wks, 8.5 days and 13.5 days of pregnancy 2 h before sacrifice. Incorporated BrdU was detected in sections
by IHC using an anti-BrdU antibody. Magnification: 400X. (B) The number of BrdU-positive epithelial cells in mammary lumina at 8 wks, pregnancy day
8.5 and pregnancy day 13.5 were counted. For each sample, cells were counted in 10 random high-power fields. Three mice were analyzed per group.
The results are expressed as the percentage (mean6S.D.) of BrdU-positive cells. *P,0.05; **P,0.01; scale bars, 50 mm.
doi:10.1371/journal.pone.0019102.g004
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e19102Figure 5. MUC1-CD increases b-catenin nuclear localization and activity in the transgenic mice. (A) IHC staining of b-catenin at 8 wks and
pregnancy day 8.5. Scale bars, 20 mm. (B) Nuclear and cytoplasmic fractions of the mammary glands from pregnancy day 13.5 females were
immunoblotted with antibodies against b-catenin, lamin B, and a-tubulin. Quantitative RT-PCR analysis of c-Myc (C) and cyclin D1 (D) mRNA levels in
8-wk-old virgin, pregnancy day 8.5 and pregnancy day 13.5 mouse mammary glands. Results are shown as mean6S.D. (n$3 for each genotype at
each time point). *P,0.05. (E) Lysates from the mammary gland of 8-wk-old virgin, pregnancy day 8.5 and pregnancy day 13.5 mice were
immunoblotted with the indicated antibodies.
doi:10.1371/journal.pone.0019102.g005
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further confirmed by statistical analysis comparing 11 breast
tumor tissues and 11 normal tissues (Fig. 6C & 6D). These data
indicate that a high abundance of MUC1-C correlates with an
elevated level of b-catenin in the nucleus and upregulation of c-
Myc and Cyclin D1 gene expression in human breast carcinomas.
Discussion
In a published study, transgenic lines overexpressing full-length
human MUC1, tail-deleted cytoplasmic MUC1 (MUC1DCT), or
tandem repeat-deleted MUC1 under the control of an MMTV
promoter were generated in an FVB mouse background [15].
Primary mammary gland tumors were observed in the MMTV-
MUC1 lines but not in either the MMTV-MUC1DCT transgenic
line or the wild-type control lines, implicating a function of
MUC1-C in tumorigenicity in mammary tissue. In agreement
with this notion, MUC1-CD was found to be sufficient for
inducing anchorage-independent growth and tumorigenicity in
cells, indicating that the MUC1-N mucin subunit is dispensable for
transformation. In the present study, we generated MMTV-
MUC1-CD transgenic mice in a C57BL/6J background. We
found that expression of MUC1-CD in luminal epithelial cells of
the mammary gland induced a mammary hyperplasia phenotype
characterized by hyperbranching in the transgenic mice at
prepuberty and early virgin stages. Although IHC analysis showed
a hyperplasia phenotype in the transgenic mice, no tumors were
observed, indicating that MUC1-CD is not sufficient to cause
tumors in the C57BL/6J background. These results suggest that
additional genotypic changes are required for cancer development
in this context. But this is not surprising given that C57BL/6J mice
are less susceptible to mammary tumorigenesis than FVB mouse
background [34,35]. However, the development of hyperplasia
indicates that MUC1-CD plays a role in mammary gland
development.
The development of the mammary gland is regulated by a
balance between proliferation and apoptosis [36,37]. MUC1-C is
involved in diverse signaling pathways that have been linked to
tumorigenesis, functioning either in promoting cell proliferation or
blocking the induction of apoptosis [38,39,40,41,42]. In this study,
Figure 6. MUC1-C is associated with increased b-catenin nuclear localization and activity in clinical breast carcinomas. (A)
Representative images of IHC staining of MUC1-C and b-catenin in sections from human breast cancer tissue and normal mammary tissues. (B)
Representative images of IHC staining of Cyclin D1 and c-Myc in sections from human breast cancer tissues and normal mammary tissues. Intensity
analysis of c-Myc (C) and Cyclin D1 (D) in sections from 11 human breast cancer tissue samples and 11 normal mammary tissue samples. The data
represented as relative fold of intensity of IHC staining in graphs were measured using Image-Pro Plus software; scale bars, 30 mm.
doi:10.1371/journal.pone.0019102.g006
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transgenic mice and wild-type littermates at stages of puberty and
pregnancy in our analysis of BrdU-positive cells but not when we
examined TUNEL-stained cells (data not shown). Our data
demonstrate that the MUC1-CD enhances mammary cellular
proliferation, rather than reducing apoptosis, at least during stages
from prepuberty to pregnancy.
Estrogen receptor is generally believed to have an essential role
in development of the mammary gland at puberty stage [1]. Given
that MUC1 stabilizes ERa, stimulates ERa-mediated transcrip-
tion, contribute to E2-mediated growth and survival of breast
cancer cells [43], we asked if the effect of MUC-CD on mammary
development is related to enhanced ER activity. Our results show
that MUC1-CD induces mammary gland hyper-branching in
both of male and female prepuberty mice, suggesting that ER has
little, if any, effect on hyperplasia phenotype in MUC1-CD
transgenic mice.
A number of studies have revealed a role of the Wnt/b-catenin
pathway in the initial stages of mammary development [44]. For
example, several Wnt genes, including Wnt3a, Wnt6, Wnt10a,
and Wnt10b, are sequentially expressed within the developing
mammary tissue between E11.25 and E11.5 (40–42 somite stage),
suggesting that Wnt/b-catenin pathway signaling is required for
the initiation of mammary gland development in embryos [45]. In
support of this finding, mice expressing Wnt inhibitors, such as
Dickkopf1 (Dkk1) [45], or that are deficient in Lef-1 [46,47]
exhibit defective embryonic mammary development. In light of
our finding that MUC1-CD induces a precocious development of
mammary gland at as early as 2 wks of age, we hypothesize that
the effect of MUC1 in the early stages of embryonic mammary
development could be through the Wnt/b-catenin pathway. Both
our IHC and nuclear fraction analyses demonstrated an elevated
b-catenin level in the nucleus in MUC1-CD transgenic mice,
suggesting that induction of mammary hyperplasia during stages
from prepuberty to pregnancy by MUC1-CD could be carried out
via regulating b-catenin while bypassing the need for hormonal
signals. However, multiple lines of evidence have demonstrated
roles for b-catenin signaling in alveologenesis but not in ductal
side-branching [48]. We observed both ductal hyper-branching
and extensive lobuloalveolar development in MUC1-CD trans-
genic mice, suggesting another mechanism through which MUC1-
CD affects ductal side branching, in addition to the b-catenin
pathway.
Upregulation of c-Myc or Cyclin D1 has been identified to
result from Wnt/b-catenin pathway activation [31,32,33]. The
Cyclin D1 protein is a cell cycle regulator that functions to
promote cellular proliferation and transformation through inhib-
iting the retinoblastoma pRB protein [49,50]. It is overexpressed
in up to 50% of human mammary ductal carcinomas in breast
cancer [51,52,53]. The c-Myc is also an oncogene and is
overexpressed in at least 15% of breast cancers. A high expression
level of c-Myc is significantly associated with a poor prognosis in
breast cancer patients [54]. Transgenic mice constitutively
expressing either MMTV-cyclin D1 or MMTV-c-Myc develop
mammary hyperplasia and mammary carcinomas [55,56,57].
Furthermore, transgenic mice overexpressing the Wnt signaling
co-receptor LRP6 driven by the MMTV promoter exhibit
activation of Wnt/b-catenin signaling, upregulation of cyclin D1
and c-Myc expression, and increased expression of the cell
proliferation marker Ki67, thereby triggering mammary hyper-
plasia [5]. MUC1-CD transgenic mice display markedly increased
levels of c-Myc and cyclin D1 in their mammary tissues at virgin
and pregnancy stages, suggesting that induction of mammary
hyperplasia by MUC1-CD likely occurs through activation of
b-catenin and subsequent upregulation of c-Myc and cyclin D1
gene expression in the mouse mammary gland.
The developing mammary gland displays many of the
properties associated with tumor progression, such as invasion,
reinitiation of cell proliferation, resistance to apoptosis, and
angiogenesis. Thus, many of the factors essential for mammary
gland development are also associated with cancer [1,58]. Indeed,
in breast carcinoma specimens, we observed that overexpression of
MUC1-C was associated with a nuclear distribution of b-catenin
in tumor tissues and increased expression of Cyclin D1 and c-Myc.
This result is similar to what we observed in MUC1-CD transgenic
mice.
In summary, the present investigation provides evidence for the
contribution of MUC1-CD to the early development of the
mammary gland. Enhanced proliferation of mammary epithelia
could be induced through activation of b-catenin and increased
expression levels of cyclin D1 and c-Myc. Deregulation of b-
catenin by MUC1-CD may also be a critical mechanism
promoting breast carcinogenesis. Therefore, finding a role for
the MUC1-CD, the minimal functional unit of MUC1, in
preneoplasia not only advances our understanding of the
molecular basis of MUC1-mediated mammary gland tumorigen-
esis but may also suggest MUC1-CD as a potential target for the
diagnosis and chemoprevention of human breast cancer.
Materials and Methods
Ethics statement
All research involving human participants have been approved
by the Institutional Review Board of Shanghai Huangpu Center
Hospital. Since paraffin-embedded human breast archival speci-
mens were analyzed anonymously, we have not obtained informed
consent from all participants involved in this study. All clinical
investigation have been conducted according to the principles
expressed in the Declaration of Helsinki.
All animal experiments were performed according to protocols
approved by the Animal Ethics Committee at the Shanghai
Jiaotong University School of Medicine, and their care was in
accord with the institution’s guidelines (Approval ID: scxk(Hu)
2004-0001).
Plasmid construction and transgenic mouse generation
A GFP-tagged human cDNA coding MUC1-CD (72 AA) was
subcloned into the EcoRI restriction site of the mouse mammary
tumor virus long terminal repeat promoter (pMMTV-LTR)
transgene cassette [28,29]. The XhoI fragment carrying the
transgene was purified and microinjected into fertilized eggs from
C57BL/6JxCBA F1 mice by the Shanghai Research Center for
Model Organisms. The genotypes of these mice were identified by
PCR analysis of their genomic DNA using the following primers:
forward 59 CTGGTCATCATCCTGCCTTT 39 and reverse 59
TTTTGGCAGAGGGAAAAAGA 39.
Semiquantitative reverse transcription PCR
Total RNA was isolated from the third mammary glands,
salivary gland, lung, ovary and kidney with TRIzol reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. DNase I-treated (Promega, Madison, WI) total
RNA was reverse transcribed with AMV reverse transcriptase
(TAKARA Biotechnology, Inc., Otsu, Japan). cDNA was
amplified using primers for GFP-CD and b-actin: GFP-CD
(forward 59AAGACCCCAACGAGAAGC 39 and reverse 59CTA-
CAAGTTGGCAGAAGTGG 39); and b-actin (forward 59
CTGGCCGGGACCTGACAGACTACC 39 and reverse 59ATC
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were separated by agarose gel electrophoresis and visualized by
ethidium bromide staining. The gels were scanned using a Tanon
imaging workstation (Tanon, Shanghai, China).
Quantitative real-time reverse transcription PCR
Quantitative RT-PCR was carried out with SYBR Green PCR
kit according to the manufacturer’s instructions (Takara Biotech-
nology, Inc., Otsu, Japan). Amplifications were performed in ABI
PRISM 7500 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA). Relative transcript quantities were
calculated using the DDCt method with b-actin as an endogenous
control for normalization. The value of each genotype at each
time point was identified by more than three samples and each
sample was repeated three times independently. The primer
sequences were as following: c-Myc (forward 59 GTACCTCG-
TCCGATTCCACG 39 and reverse 59 GGGTTTGCCTCT-
TCTCCACAG 39); cyclin D1 (forward 59 GCGTACCCTGA-
CACCAATCTC 39 and reverse 59 CTCCTCTTCGCACTTCT-
GCTC 39); b-actin (forward 59 TGTCCACCTTCCAGCAGA-
TGT 39 and reverse 59 AGCTCAGTAACAGTCCGCCTAG 39).
Immunohistochemistry (IHC)
Mammary gland specimens were fixed in 4% paraformaldehyde
in PBS and dehydrated prior to embedding in paraffin. For
histological analysis, 6-mm sections were cut and stained with
hematoxylin and eosin according to standard procedures. For IHC
analysis, paraffin-embedded sections were deparaffinized with
xylene and treated with gradually decreasing concentrations of
ethanol, then heated at 92–96uC for 30 min in 10 mM citrate
buffer (pH 6.0) for antigen retrieval. Sections were treated with 1%
hydrogen peroxidase in PBS for 10 min to block endogenous
peroxidase activity and blocked for 1 hour in 5% bovine serum
followed by staining overnight at 4uC with rabbit anti-GFP (Cell
Signaling Technology, Danvers, MA) and rabbit anti-b-catenin
antibodies (Santa-Cruz Biotechnology, Inc., Santa-Cruz, CA) for
mouse tissues and mouse anti-c-Myc and mouse anti-cyclin D1
antibodies for human specimens. The staining procedure followed
the manufacturer’s instructions for the ABC staining system
(Santa-Cruz Biotechnology).
Immunofluorescence(IF)
Mammary glands were embedded carefully in O.C.T. Com-
pound (Sakura Finetek USA, inc., Torrance, CA) and stored at -
80uC. 6-mm sections were washed with PBS for 5 minutes to
remove excess O.C.T. and fixed in freshly prepared 4%
paraformaldehyde for 10 minutes at room temperature. The
slides were then permeabilized with 0.5% Triton X-100 in PBS for
5 minutes and blocked for 1 hour in 5% goat serum in PBS
followed by incubating with primary antibody rabbit anti-GFP
(Cell Signaling Technology, Danvers, MA) overnight at 4uC, and
fluorescent-conjugated secondary antibody for 30 minutes. Finaly,
the slides were rinsed with PBS and mounted with VECTA-
SHIELD-mounting medium (H-1200, Vector Laboratories, Inc.,
Burlingame, CA).
Mammary whole-mount staining
Whole-mount staining was performed according to standard
protocols (http://mammary.nih.gov/index.html). Briefly, the in-
guinal mammary glands were harvested and spread on glass slides,
fixed overnight in Carnoy’s fixative (60% ethanol, 30% chloro-
form, and 10% glacial acetic acid) at room temperature and
washed in 70% ethanol for 15 min, then transferred gradually to
distilled water. The slides were stained in carmine alum solution
overnight, gradually washed through a series of 70%, 95%, and
100% ethanol for 15 min and cleared in xylene. Images of the
whole mounts were acquired with an Olympus digital camera
using the same magnification and lighting conditions.
BrdU staining assay
Mammary cell proliferation was measured by the incorporation
of 5-bromo-29-deoxyUridine (BrdU). BrdU was administered
intraperitoneally to mice at a dosage of 5 mg/kg body weight
2 h before sacrifice. BrdU incorporation was detected in sections
by IHC staining with Rat anti-BrdU (Santa-Cruz Biotechnology).
For each mammary sample, BrdU-positive cells and total
mammary epithelium cells were counted in 10 random high-
power fields (4006) by an investigator unaware of the animal’s
genotype. The results are presented as a percentage.
Western blot analysis
Nuclear and cytoplasmic fractions from mouse mammary gland
tissues were prepared using the NE-PER Nuclear and Cytoplasmic
Extraction Reagents kit (PIERCE Biotechnology, Rockford, IL)
according to the manufacturer’s instructions. Mammary protein
lysates were prepared as described previously [12]. Proteins were
subjected to separation by SDS-PAGE, transferred to nitrocellu-
lose membranes, and probed with rabbit anti-b-catenin, goat anti-
lamin B (Santa-Cruz Biotechnology), mouse anti-a-tubulin
(Sigma-Aldrich Co., St. Louis, MO), mouse anti-c-Myc, mouse
anti-Cyclin D1 and goat anti-b-actin (Santa-Cruz Biotechnology).
Human breast clinical sample collection
Paraffin-embedded archival specimens were collected from the
Department of Breast Surgery, Shanghai Huangpu Central
Hospital, China. A total of 11 breast cancer specimens and 11
normal mammary specimens were enrolled in this study, as
determined pathologically. These patients did not receive any
preoperative adjuvant radiation or chemotherapy.
Statistical analysis
All quantitative data in this study are presented as mean6
standard deviation. A two-tailed Student t-test was used to analyze
comparisons between two groups. P,0.05 was considered
statistically significant.
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